METTL3蛋白的表达水平对NSCLC患者PD-1抑制剂疗效的预测价值  

Predictive value of METTL3 protein expression level in the efficacy of PD-1 inhibitors in patients with NSCLC

作　　者：赵薇[1] 赵有财[1] 丁薇[2] 杨小兵[1] 陈炜[2] ZHAO Wei;ZHAO Youcai;DING Wei;YANG Xiaobing;CHEN Wei(Department of Pathology,the Affiliated Nanjing Hospital of Nanjing Medical University,Nanjing 210006;Department of Respiratory and Critical Care Medicine,the Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University,Huai'an 223300,China)

机构地区：[1]南京医科大学附属南京医院病理科,江苏南京210006 [2]南京医科大学附属淮安第一医院呼吸与危重症医学科,江苏淮安223300

出　　处：《南京医科大学学报（自然科学版）》2021年第6期879-884,共6页Journal of Nanjing Medical University(Natural Sciences)

基　　金：淮安市自然科学研究计划项目(HAB 201928)。

摘　　要：目的:探讨甲基化转移酶3(methyltransferase-like 3,METTL3)联合程序死亡配体1(programmed death ligand 1,PD-L1检测在非小细胞肺癌(non-small cell lung cancer,NSCLC)患者程序性细胞死亡蛋白1(programmed death cell protein 1,PD-1)抑制剂治疗效果和预后预测中的价值。方法:收集NSCLC患者原发病灶组织蜡块标本,免疫组织化学检测PD-L1、METTL3的蛋白表达情况,并分析其与NSCLC患者PD-1抑制剂治疗效果和预后间的联系。结果:符合入组标准的患者共228例;其中,METTL3蛋白的表达情况与病理类型、美国东部肿瘤合作组织(Eastern American Oncology Collaborative Group,ECOG)评分、治疗方案、治疗效果以及实体瘤疗效评价标准(response evaluation criteria in solid tumors,RECIST)等因素有关;METTL3蛋白高表达患者的中位无进展生存期(progression-free-survival,PFS)为12.33个月,METTL3蛋白低或无表达患者的中位PFS为6.50个月;在接受PD-1抑制剂治疗的NSCLC患者中,METTL3蛋白高表达患者有较长的PFS;METTL3蛋白高表达患者的中位总体生存期(overall-survival,OS)为23.54个月,METTL3蛋白低或无表达患者的中位OS为20.93个月,METTL3蛋白高表达与较长的OS相关。结论:METTL3蛋白可能为预测NSCLC PD-1抑制剂免疫治疗效果的标志物。Objective:This study aims to explore METTL3 combined with programmed death cell ligand 1(PD-L1)detection in predicting the therapeutic effect and prognosis of NSCLC patients with programmed death cell protein 1(PD-1)inhibitors treatment.Methods:Primary lesion tissues from NSCLC patients were collected. The protein expression of PD-L1 and METTL3 was detected by immunohistochemistry,and the association of METTL3 with the effect of PD-1 inhibitor treatment and prognosis in patients with NSCLC was analyzed. Results:A total of 228 cases were collected. Among them,the protein expression of METTL3 was related to the pathological type,Eastern American Oncology Collaborative Group(ECOG)score,therapeutic plan,therapeutic effect and Response Evaluation Criteria in Solid Tumors(RECIST)factors. Patients with high METTL3 protein expression had a median progression-freesurvival(PFS)of 12.33 months,while those with low or no METTL3 protein expression had a median PFS of 6.50 months. In NSCLC patients treated with PD-1 antibody,high METTL3 protein expression was associated with better PFS. The median overall-survival(OS)of patients with high METTL3 proteine xpression was 23.54 months,and OS of patients with low or no METTL3 protein expression was20.93 months. Patients with high METTL3 protein expression were associated with better OS. Conclusion:METTL3 protein may be a new target for predicting the efficacy of PD-1 inhibitors treatment in patients with NSCLC.

关 键 词：NSCLC 免疫治疗 m6A METTL3 PD-L1 

分 类 号：R734.2[医药卫生—肿瘤]